Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,933 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer's Disease
Interventions
LY450139 dihydrate, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
La Jolla, California • Indianapolis, Indiana • St Louis, Missouri + 3 more
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Conditions
Alzheimer's Disease, Hypogonadism
Interventions
AndroGel (Solvay Pharmaceuticals)
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
55 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Results available

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

NCT01434667
Conditions
Mild Cognitive Impairment
Interventions
APOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Conditions
Alzheimer's Disease
Interventions
AC-1204, Placebo
Drug
Lead sponsor
Cerecin
Industry
Eligibility
66 Years to 90 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 69 more
Conditions
Alzheimer's Disease
Interventions
Donepezil, AZD3480
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida
Conditions
Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia, Cognitive Decline, Dementia, Alzheimer Type
Interventions
Renew NCP-5
Device
Lead sponsor
Renew Research, LLC
Other
Eligibility
55 Years to 85 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Irvine, California • Lady Lake, Florida + 7 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Heart Rate and Breathing Effects on Attention and Memory

NCT05602220
Conditions
Aging, Alzheimer Disease, Age-related Cognitive Decline
Interventions
Brain training, Paced breathing
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Dementia, Alzheimer Disease
Interventions
Partners in Dementia Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Boston, Massachusetts • Brockton, Massachusetts • Oklahoma City, Oklahoma + 3 more
Completed No phase listed Observational Accepts healthy volunteers

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)

NCT03718494
Conditions
Alzheimer Dementia
Interventions
Brain Magnetic Resonance Imaging (MRI), F-18 Florbetapir Positron Emission Tomography (PET) Imaging, F-18 AV-1451 Positron Emission Tomography (PET) Imaging, Neuropsychological Testing
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
49 Years to 72 Years · Female only
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 3 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Gamma-Music Based Intervention for Mild Alzheimer's Disease

NCT05984524
Conditions
Alzheimer Disease
Interventions
Gamma-Music Based Intervention
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
50 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting No phase listed Observational Accepts healthy volunteers

ADRC Clinical Cohort (Alzheimer's Disease)

NCT06703541
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
25 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Alzheimer's Disease
Interventions
BPN14770, Placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
25 Years to 90 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Kalamazoo, Michigan
Not listed No phase listed Observational Accepts healthy volunteers

Implications of Amyloid Pathology

NCT00900770
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Alzheimer Disease
Interventions
[11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Alzheimer's Disease
Interventions
Rivastigmine, memantine
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Paterson, New Jersey
Completed Phase 2 Interventional Results available

Trial of Rifaximin in Probable Alzheimer's Disease

NCT03856359
Conditions
Alzheimer's Disease
Interventions
Rifaximin 550 milligrams (MG)
Drug
Lead sponsor
Duke University
Other
Eligibility
55 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Dementia, Mixed, Dementia Mild, Dementia Moderate, Traumatic Brain Injury, Alzheimer Disease
Interventions
Telehealth-delivered Care Coordination Program
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Alzheimer Disease
Interventions
[11C]-CS1P1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Alzheimer Disease, Alzheimer Disease, Late Onset
Interventions
MemorEM 1000
Device
Lead sponsor
NeuroEM Therapeutics, Inc.
Industry
Eligibility
63 Years to 84 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Alzheimer Disease
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
21 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
8
States / cities
Sun City, Arizona • Stanford, California • Tampa, Florida + 5 more
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
Conditions
Alzheimer's Disease With Vascular Pathology
Interventions
CY6463, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Scottsdale, Arizona • Miami, Florida • Honolulu, Hawaii + 2 more
Conditions
Alzheimer's Disease
Interventions
Crenezumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 42 more